Hanuo Medical's Science and Innovation Board IPO has been accepted. The core product LifemotionECMO system has been implemented in over 140 hospitals nationwide.

On December 23, Shenzhen Hanno Medical Technology Co., Ltd. (Hanno Medical) submitted its application for an IPO on the STAR Market of the Shanghai Stock Exchange. CITIC SEC is the sponsor institution, with plans to raise 1.062 billion yuan. According to the prospectus, Hanno Medical is a high-end Innovative Medical Management equipment company with global competitiveness potential. It focuses on technological innovation in the field of extracorporeal life support (ECLS), dedicated to providing stable and reliable circulation support and oxygenation technology products to the world with forward-looking medical engineering technology. The company focuses on the platform key technology of extracorporeal life support (ECLS). Its core product, the Lifemotion extracorporeal membrane oxygenation (ECMO) system, was listed in 2023, making it the first domestic company in China to successfully develop and market an ECMO system. This achievement marked a breakthrough in China's "zero" in this field, as previously only a few countries such as the United States, Germany, and Italy had the industrial capability for this product. The company also has a global competitive edge, being one of the few manufacturers in the world to have a complete layout of both ECMO equipment and consumables. As the first domestically produced ECMO system to enter the international market, the Lifemotion ECMO system obtained EU CEMDR certification in early 2025, commercializing the ECMO system both domestically and internationally and showcasing the development level of China's new quality in medical device production, signifying that domestically produced high-end medical devices now have international competitiveness. Through years of independent research and development and innovation investment, Hanno Medical has assembled an interdisciplinary research and development team covering areas such as extracorporeal circulation, biomedical engineering, electromechanical, materials, precision manufacturing, and clinical medicine. They have successfully overcome multiple key core technologies and achieved a breakthrough in the full chain from the principle to the product of domestic ECMO. As of June 30, 2025, the company's core product, the Lifemotion ECMO system, has covered over 140 hospitals nationwide and successfully entered top-tier hospitals such as Beijing Anzhen Hospital of Capital Medical University, the General Hospital of the PLA (301 Hospital), West China Hospital of Sichuan University, and the renowned public hospital Queen Mary Hospital in Hong Kong. In early 2025, the Lifemotion ECMO system obtained EU CEMDR certification, becoming the first domestically produced ECMO system to enter the international market. As of the date of the prospectus signing, the company has delivered orders to Europe, South America, Africa, and has applied for product registration in multiple countries and regions globally. The company adheres to clinical demand-oriented principles and has mastered innovative high-security, high-stability hardware and software architecture design, artificial heart/lung design and manufacturing, among other key technologies. They have built a system that includes (1) a high-security and high-stability R&D platform for extracorporeal life support auxiliary equipment; (2) an R&D and manufacturing platform for high-performance artificial heart and lung and consumables; (3) an R&D and coating process platform for high-performance medical coatings as the underlying technology platforms to support the three. Based on its independent core technology platform, the company has laid out a range of extracorporeal circulation support systems covering the full range of flow rates. By matching organ perfusion and oxygenation parameters precisely, they provide comprehensive, flexible, multidisciplinary life support solutions. Currently, approved and under-study product pipelines cover four major solutions: extracorporeal membrane oxygenation system (ECMO), extracorporeal cardiopulmonary resuscitation system (ECPR), extracorporeal cardiopulmonary support system (CPS), and low-flow extracorporeal circulation support system (Low-Flow). These solutions extend from ultimate life support to critical care support, complex surgeries, organ transplants, and innovative therapies, promising vast market prospects and business potential in the future. The successful development of the ECMO system has validated the company's technical capabilities in providing high-flow cardiopulmonary support. Faced with diverse and potentially huge clinical demand in extracorporeal life support, the company will focus on the blank area of extracorporeal life support using its core product, Lifemotion ECMO system, to tackle unsatisfied clinical needs. By focusing on core technological independence, diversifying the supply chain, and promoting ecological synergy, the company aims to build an industry chain cluster, lead domestic substitution and global expansion, and drive the universalization of high-end life support technology worldwide. The company plans to publicly issue no more than 25.7515 million RMB ordinary shares in this offering. The use of proceeds has been approved by the first meeting of the Board of Directors and the 2025 third extraordinary general meeting of shareholders. If the stock offering is successful, the raised funds (after deducting issuance expenses) will be invested in the following projects, depending on their urgency and importance. Financially, for the years 2022, 2023, 2024, and January to June 2025, the company achieved operating income of 0, 29.8311 million, 49.3088 million, and 37.3453 million RMB respectively. During the same period, the net profits were approximately -64.7883 million, -341 million, -183 million, and -82.2732 million RMB respectively.